Foghorn Therapeutics Inc Aktie News

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Kristian Humer will join the company as Chief Financial Officer (CFO) on April 16, 2024. Mr. Humer joins Foghorn with over 14 years of di...

First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024

Company presentation and fireside chat on April 11th at 11:45 a.m. ET Company presentation and fireside chat on April 11th at 11:45 a.m. ET

Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs

• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in Cowen's 44th Annual Health Care Conference, which is taking place on March 4–6, 2024, at the Boston Marriott Copley...

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will b...